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ABSTRACT 
Objective: This study aimed to analyze doxorubicin and doxorubicinol levels in Dried Blood Spot (DBS) from 25 breast cancer patients who 
received doxorubicin in their therapeutic regiment.  
Methods: DBS samples were extracted by protein precipitation method and analyzed using Ultra Performance Liquid Chromatography tandem 
Mass Spectrometry (LC-MS/MS), with the Acquity UPLC BEH C18 Waters chromatography column (2.1 x 100 mm x 1.7 μm). The mobile phase 
consisted of 0.1% acetic acid (eluent A) and acetonitrile (eluent B) with gradient elution; the flow rate was 0.15 ml/min and runtime, 7 min. This 
method was linear within the concentration range of 10–200 ng/ml for doxorubicin and 4–100 ng/ml for doxorubicinol.  
Result: The analysis results showed that doxorubicin levels were in the range of 11.01 ng/ml to 93.75 ng/ml and doxorubicinol was 5.80 ng/ml to 
58.57 ng/ml.  
Conclusion: Cumulative doses of all patients were in the range of 49.11 mg/m2to 303.70 mg/m2, which have cardiomyopathy incidence rates<4%. 
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INTRODUCTION 
Doxorubicin is one of the anti-cancer drugs effectively used in the 
treatment of breast cancer as adjuvant chemotherapy. Doxorubicin 
is an anthracycline drug used as an anticancer drug with a 
mechanism to form complexes with DNA and inhibit DNA-
dependent synthesis of mRNA. In the body, doxorubicin is 
metabolized into more active metabolites, namely doxorubicinol as 
the main metabolite and other metabolites, namely adriamyclic 
aglycones. Doxorubicinol has long-term side effects, namely 
cardiotoxic with accumulating concentrations. Doxorubicinol can 
disrupt the Ca2+ion pump, which results in disrupted 
Ca2+homeostasis. The use of doxorubicin in the long term causes the 
accumulation of doxorubicinol in the body, which can increase the 
risk of heart problems. Current evidence indicates that the incidence 
of cardiomyopathy at a rate of 4% at doses of 500-550 mg/m2, 18% 
at doses of 551-600 mg/m2 and 36% at doses>600 mg/m2 (all 
cumulative doses) [1, 2]. 
Doxorubicin is metabolized by carbonyl-1-reductase (CBR1) and 
carbonyl-3-reductase (CBR3) enzymes to doxorubicinol. Genetic 
polymorphism in CBR3 associated with differences in cardiac 
outcomes in pediatric patients consuming doxorubicin and 
polymorphism in CBR1 correlated with high levels of doxorubicin so 
that the levels of intracellular doxorubicinol are low [3,4]. Based on 
this, Therapeutic Drug Monitoring (TDM) is needed for breast 
cancer patients who received doxorubicin in their treatment 
regimens. Doxorubicin TDM can be carried out by simultaneous 
analysis of doxorubicin and doxorubicinol in blood. 
In this study, analysis of doxorubicin and doxorubicinol in Dried 
Blood Spot (DBS) of breast cancer patients was carried out. DBS 
are innovative bio sampling techniques in which blood samples 
are imprinted on absorbent paper or other material paper [5]. The 
volume of blood samples needed using this technique tends to be 
less than the venipuncture technique, which requires more sample 
volume. Therefore, sampling using this technique further 
increases patient comfort. DBS samples from 25 breast cancer 
patients were extracted by protein precipitation method and 
analyzed using Liquid Chromatography tandem Mass 
Spectrometry (LC-MS/MS). The results of the analysis will be seen 
quantitatively as a form of Therapeutic Drug Monitoring (TDM) in 
breast cancer patients, who received the document in this 
therapeutic regimen for the future. 
MATERIALS AND METHODS 
Chemical and reagents 
Doxorubicin HCl (Zhe Jiang Hisun Pharmaceutical Co. Ltd. China), 
doxorubicinol (Toronto Research Chemical, Canada) and 
hexamethylphosphoramide as internal standard (Sigma-Aldrich, 
USA). Reagents such as methanol, acetonitrile, acetic acid obtained 
from Merck Co. Ltd. (Darmstadt, Germany). Ultrapure water from 
Sartorius Water Filter System. Whole blood was obtained from The 
Indonesia Red Cross (Jakarta, Indonesia). Perkin Elmer 226 paper 
from Perkin Elmer (Waltham, USA). 
Preparation of stock solutions, calibration samples, and quality 
control samples 
Doxorubicin HCl, doxorubicinol, and hexamethylphosphoramide 
(HMPA) as internal standard were prepared by diluting them in 
methanol to obtain the concentration of 1 mg/ml for doxorubicin 
HCl, HMPA and 0.5 mg/ml for doxorubicinol. Doxorubicin HCl and 
doxorubicinol stock solutions were used to prepare a working 
solution containing 0.01 g/ml doxorubicin HCl and doxorubicinol in 
methanol. Calibration samples were prepared by diluting working 
solution using whole blood to obtain calibration range of 10-200 
ng/ml for doxorubicin HCl and 4-100 ng/ml for doxorubicinol, at 
seven-level concentrations each. Quality control solutions were 
prepared at 30 ng/ml (QCL), 100 ng/ml (QCM), and 150 ng/ml 
(QCH) for doxorubicin and at 12 ng/ml (QCL), 50 ng/ml (QCM), and 
75 ng/ml (QCH) for doxorubicinol by diluting working solution in 
whole blood. 
Sample preparation 
Calibration and quality control samples were prepared by pipetting 
30 µl aliquots from appropriately spiked whole blood onto the 
Perkin Elmer 226 paper. This was allowed to dry at room 
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temperature for 3 h. DBS discs were made by cutting the blood spot 
from the Perkin Elmer 226 paper and putting it into a microtube. 
Twenty-five μl of 0.1 µg/ml HMPA was added to the microtube and 
mixed well. Then was extracted using 300 µl distilled water, then 
was vortexed for 10 seconds and was sonicated for 30 min. After 
that, 300 µl methanol was added into the microtube and was 
vortexed for 10 seconds and was sonicated for 10 min. It was then 
centrifuged for about 10 min at 11200 G-force. Five hundred µl 
supernatant was transferred to a flask and was evaporated at 55 °C 
for 20 min under the gentle stream of nitrogen. The dried extract 
was reconstituted with 100 µl of mobile phase and 10 µl aliquot was 
injected into LC-MS/MS system. 
LC-MS/MS conditions 
The experiment was performed on an ACQUITY™ UPLC system 
(Waters Corp., Milford, MA, USA) and a Xevo TQD triple quadrupole 
mass spectrometer (Waters Corp., Manchester, UK) equipped with 
positive electrospray ionization (ESI+). All data were acquired in 
centroid mode by the MasslynxTM NT4.1 software and analyzed by 
QuanLynxTM programme (Waters Corp., Milford, MA, USA). The 
analyte was separated on Acquity® UPLC BEH C18 column (1.7 μm, 
2.1 mm × 50 mm, Waters, Milford, MA, USA); column temperature 
40oC; and the injection volume was 10 µl.  
The mobile phase consisted of 0.1% acetic acid (eluent A) and 
acetonitrile (eluent B) at 0.15 ml/min. A gradient program was 
performed for the elution. Initial composition of eluent was 10% A, 
which was maintained for 5 min, followed by reducing its 
composition to 5% A at the next two min. Total analytical time was 7 
min. The MS condition was using electrospray ionization positive for 
doxorubicin, doxorubicinol, and hexamethylphosphoramide (HMPA) 
with m/z values: 544.22>397.06; 546.22>363.05; 180.03>135.16, 
respectively. The capillary voltage used was 3.0 kV. Nitrogen 
temperature and flow rate were controlled at 450 °C and 500 l/h. 
Argon was used as the collision gas. The cone and collision voltage 
doxorubicin, doxorubicinol, and hexamethylphosphoramide were 
46V, 42V, 28V and 10V, 26V, 14V, respectively. 
Method validation  
Method was validated according to FDA 2018 and EMEA 2011 as the 
guideline of bioanalysis [10,11]. 
The lower limit of quantification (LLOQ) 
LLOQ was 10 ng/ml for doxorubicin and 4 ng/ml for doxorubicinol, 
which still fulfill the precision and accuracy requirement. It was 
tested using 5 replicates. It claimed to fulfill the requirement if the 
%diff and %CV value are within 20%. 
Calibration curve 
The working solution containing doxorubicin and doxorubicinol 
which diluted by whole blood to get seven concentration levels: 10, 
15, 30, 50, 100, 150, and 200 ng/ml for doxorubicin 4, 6, 12, 25, 50, 
75, 100 ng/ml for doxorubicinol. Calibration samples were spotted 
to the Perkin Elmer 226 paper according to the procedure explained 
above. Calibration curve measure based on the ratio of doxorubicin 
and doxorubicinol area to hexamethylphosphoramide area. The 
correlation coefficient (r) was 0.9878 for doxorubicin and 0.9929 for 
doxorubicinol. 
Selectivity 
The representative chromatograms resulting from the UPLC-MS/MS 
analysis of blank DBS and spiked LLOQ of doxorubicin, 
doxorubicinol, and hexamethylphosphoramide are given in fig. 1a 
and b. There were no significantly interfering peaks due to the 
endogenous components or reagents that were observed for 
doxorubicin, doxorubicinol, and hexamethylphosphoramide. 
Precision and accuracy 
Quality control samples were prepared at four concentration levels 
for each analyte, which were: 10 ng/ml (LLOQ), 30 ng/ml (QCL), 100 
ng/ml (QCM), 150 ng/ml (QCH) for doxorubicin and 4 ng/ml 
(LLOQ), 12 ng/ml (QCL), 50 ng/ml (QCM), 75 ng/ml (QCH) for 
doxorubicin by diluting the working solutions in whole blood. Each 
concentration was tested using 5 replicates by within-run and 
between-run. It fulfills the requirement if %diff and %CV obtained 
within 20% for LLOQ and within 15% for other concentrations 
besides LLOQ.  
Recovery 
The mean extraction recoveries of doxorubicin were 81.59%, 
80.49%, and 82.43% (n = 3) at the concentration of QCL, QCM, and 
QCH, with %CV values of 1.68%, 9.30%, and 8.06%, respectively. 
The mean extraction recoveries of doxorubicinol were 81.92%, 
81.30%, and 86.71% (n = 3) at the concentration of QCL, QCM, and 
QCH, with % CV values of 5.55%, 1.58%, and 0.78%, respectively. 
While for hexamethylphosphoramide was 89.82% with %CV value 
was 3.35%. 
Carryover 
The measured peak area of the blank sample injected after ULOQ 
calibration standard was between 2.20-13.41% of the peak area of 
the analyte at LLOQ for doxorubicin, between 0.94-10.37% of the 
peak area of the analyte at LLOQ for doxorubicinol and between 
0.18-0.36% of the peak area of the analyte at LLOQ for 
hexamethylphosphoramide. 
Dilution integrity 
The dilution integrity testing results were acceptable because the 
dilution still fulfills accuracy and precision requirements with %diff 
and %CV not more than 15%, which was diluted in human blank 
whole blood until the concentration of QCH and a half of QCH. 
Matrix effects 
The internal standard normalized matrix factor value of doxorubicin 
were 0.93 and 0.91 at the concentration of QCL and QCH, with %CV 
of 5.07% and 7.69%, respectively. The internal standard normalized 
matrix factor value of doxorubicinol was 0.91 and 0.96 at the 
concentration of QCL and QCH, with %CV of 7.02% and 6.70%, 
respectively. While for the hexamethylphosphoramide, the mean 
matrix effect was 93.24% with %CV of 5.28%. These data indicate 
that the ME (ion suppression or enhancement) from human plasma 
was negligible under the current conditions. 
Stability 
Storage of stock solutions of doxorubicin, doxorubicinol and 
hexamethylphosphoramide in methanol at room temperature for 24 
h and in the refrigerator (-4 °C) for 1 mo (long term stability) did not 
alter the analyte of doxorubicin, doxorubicinol, and 
hexamethylphosphoramide. The stability test results of doxorubicin 
and doxorubicinol in DBS is stable enough during sample 
preparation, storage conditions and autosampler. 
Application of the method 
After approval (032/KEPK/III/2019) by the Ethics Committee of 
Dharmais Cancer Hospital, a total of 25 breast cancer patients who 
were taking chemotherapy treatment with doxorubicin on any 
stage of breast cancer enrolled in the study. They signed the 
informed consent prior participating in this study. The study 
inclusion criteria were patient that has been diagnosed with 
breast cancer who receive doxorubicin in their therapy regimen, 
while the exclusion criteria were the patient who has not got 
doxorubicin therapy on their regiment therapy or declared they 
were unwilling to participate in the study by not signing the 
informed consent sheet. Finger prick blood samples were collected 
from 25 breast cancer patients of Dharmais Cancer Hospital, 
Jakarta, Indonesia. Blood samples are taken 40 min after 
doxorubicin administration. Around 100 μL blood samples were 
collected from the fingertips. Blood was taken by finger prick 
technique using a lancet and the first drop of blood from fingertip 
was thrown away by rubbing it with an alcohol swab; then, the 
blood drops were collected in a 0.5 ml K3EDTA microtube. After 
that, 30 μL aliquot blood was immediately transferred to DBS 
paper using a calibrated pipette. Next, the DBS paper was dried at 
room temperature for 3 h. After it was dried, DBS paper was 
stored in a seal bag where the silica gel was inserted into it. 
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RESULTS AND DISCUSSION 
Chromatography and sample preparation 
There are several previous studies about doxorubicin and 
doxorubicinol analysis, such as by Sottani, Poggi, Melchiorre, et al. in 
2013 and study by DiFrancesco, Griggs, Donnelly, et al. in 2007. The 
two studies used UHPLC-MS/MS and human plasma as sample; 
extracted by solid phase extraction [6,7]. However, analysis of drugs 
with plasma sample has several disadvantages such as invasive 
sampling and needed more volume of sample [8]. For this reason, in 
this study, DBS sample is choosen because it is less invasive and it 
needed less volume of sample [9]. 
Sensitive and selective methods were needed for DBS technique 
because it has low concentration and it use whole blood, which still 
contains many interferences; hence, LC-MS/MS is suitable to analyze 
it. This study was performed using Acquity UPLC C-18 BEH (2.1 x 
100 mm), 1.7 μm to separate compound of interest with total 
analytical time 7 min. Sample preparation was done by spotted 30 μL 
aliquot blood on Perkin Elmer 226 paper. Extraction process was 
performed as it stated earlier. Retention time of doxorubicin, 
doxorubicinol and HMPA are 2.93; 2.93; and 3.03, respectively (fig. 1) 
Method validation 
Calibration curve obtained was linear in the range within 10-200 ng/ml 
for doxorubicin and 4-100 ng/ml for doxorubicinol with correlation 
coefficient (r) value ≥0.9932 and ≥0.9988, respectively. Precision and 
accuracy’s result were shown in table 1. The data demonstrate that the 
accuracy and precision values are within the acceptable criteria based on 







Fig. 1: Chromatogram of blank (a), LLOQ (b), QCL (c), QCM (d) and QCH (e) 
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Table 1: The intra-day accuracy and precision of doxorubicin (up) and doxorubicinol (down) 
Nominal conc. (ng/ml) Mean accuracy (%diff) Precision (%CV) 
10.00 -12.16 to 0.87 5.60 
30.00 -11.04 to 11.59 11.87 
100.00 -7.84 to 11.00 8.82 
150.00 -10.65 to 11.45 9.77 
Nominal conc. (ng/ml) Mean accuracy (%diff) Precision (%CV) 
10.00 -8.17 to 15.18 9.22 
30.00 -5.14 to 7.95 5.31 
100.00 -13.15 to 11.76 11.01 
150.00 8,31 to 13,38 1.91 
[
Clinical application 
The results of the analysis on 25 samples showed that all samples 
contained doxorubicin and doxorubicinol with a certain 
concentration as in fig. 4. The highest doxorubicin content was 
found in SN 17 patients of 93.75 ng/ml and the lowest level of 
11.01 ng/ml was present in SN 10 (fig. 2). Based on the data 
obtained, it can be concluded that doxorubicin levels in the DBS 
between patients vary widely. This variation between patients was 
also found in the results of doxorubicinol analysis. The highest 
doxorubicinol levels were present in SN 24 of 58.57 ng/ml and the 
lowest levels of 5.80 ng/ml were present in patients with SN 14 
(fig. 3). The results of the analyzes obtained may have varied level 
of concentration because based on the previous study stated that 
CBR1 gene polymorphism correlated with high concentrations of 
doxorubicin and the possibility of intracellular conversion to 
lower doxorubicinol in the patient's body [3]. Most of the patients 
have doxorubicin concentration level higher than doxorubicinol. 
Whereas, in 3 patients, the concentration levels of doxorubicinol 
were found to be much higher compared to the concentration 
levels of doxorubicin in SN 8, SN 10 and SN 24 patients. Other 
previous study by Covarrubias et al., (2009) stated that the higher 
concentration of doxorubicinol has a relationship with 
untranslated CBR1 polymorphism [12]. 
 
 




Fig. 3: Chromatogram of highest (up) and lowest (down) doxorubicinol levels 
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Fig. 4: Graphic of inter-patient doxorubicin and doxorubicinol levels in DBS samples 
 
Based on study, it was stated that the incidence of cardiomyopathy 
increased at a rate of 4% at doses of 500-550 mg/m2, 18% at doses of 
551-600 mg/m2 and 36% at doses>600 mg/m2 (all cumulative doses) 
[2]. In this study, the obtained cumulative doses of all patients were in 
the range of 49.11 mg/m2 to 303.70 mg/m2 based on doses that 
accepted by the patient according to the body surface area. It can be 
concluded that all of the patients have cardiomyopathy incidence rates 
of<4%. Based on the patient's medical record, there were no records 
of heart problems in the patient, which means that chemotherapy in 
Dharmais Cancer Hospital has been done well. 
CONCLUSION 
The method successfully applied to 25 breast cancer patients, which 
resulted in doxorubicin concentration ranged from 11.01 ng/ml to 
93.75 ng/ml and doxorubicinol concentration ranged from 5.80 
ng/ml to 58.57 ng/ml. Cumulative doses of all patients were in the 
range of 49.11 mg/m2to 303.70 mg/m2, which have cardiomyopathy 
incidence rates<4%. This study offers efficiency for therapeutical 
drug monitoring doxorubicin therapy that has the potential to 
increase the survival rate of the breast cancer patient. 
ACKNOWLEDGMENT 
This study was supported by Directorate of Research and 
Community Service (DRPM) Universitas Indonesia for the financial 
support this research with Grant Number: NKB-0203/ 
UN2.R3.1/HKP.05.00/2019 and Dharmais Cancer Hospital, Jakarta, 
Indonesia. 
FUNDING 
Directorate of Research and Community Service (DRPM) Universitas 
Indonesia. 
AUTHORS CONTRIBUTIONS 
Prof. Dr. Yahdiana Harahap-Design, the study, and be responsible for 
the whole study and create the report, Sabrina Nur Amalia-Perform 
the blood sampling and analyze the dried blood spot samples, Aldhi 
Anarta-Perform the optimization and development of the bioanalytical 
method, Ramadhan-Supervise the clinical part of the research. 
CONFLICT OF INTERESTS 
Declared none 
REFERENCES 
1. Wells B, Dipiro J, Schwinghammer T, Dipiro C. 
Pharmacotherapy Handbook. Pharmacotherapy Handbook; 
2009. https://doi.org/10.1345/aph.10237. 
2. Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S. 
Role of the endothelium in doxorubicin-induced 
cardiomyopathy. JACC Basic Transl Sci 2018;3:861–70. 
3. Lal S, Sandanaraj E, Wong ZW, Ang PCS, Wong NS, Lee EJD, et al. 
CBR1 and CBR3 pharmacogenetics and their influence on 
doxorubicin disposition in Asian breast cancer patients. Cancer 
Sci 2008;99:2045-54. 
4. Schaupp CM, White CC, Merrill GF, Kavanagh TJ. Chemico-biological 
interactions metabolism of doxorubicin to the cardiotoxic 
metabolite doxorubicinol is increased in a mouse model of chronic 
glutathione deficiency: a potential role for carbonyl reductase 3. 
Chem Biol Interactions 2015;234:154–61. 
5. Evans G. A handbook of bioanalysis and drug metabolism. 
Taylor and Francis; 2004. Available from: 
https://books.google.co.id/books?id=vKgikgEACAAJ [Last 
accessed on 15 Nov 2019] 
6. Sottani C, Poggi G, Melchiorre F, Montagna B, Minoia C. 
Simultaneous measurement of doxorubicin and reduced 
metabolite doxorubicinol by UHPLC–MS/MS in human plasma 
of HCC patients treated with TACE. J Chromatogr B: Anal 
Technol Biomed Life Sci 2013;916:71–8. 
7. DiFrancesco R, Griggs JJ, Donnelly J, DiCenzo R. Simultaneous 
analysis of cyclophosphamide, doxorubicin and doxorubicinol 
by liquid chromatography coupled to tandem mass 
spectrometry. J Chromatogr B: Anal Technol Biomed Life Sci 
2007;852:545–53. 
8. Zakaria R, Allen KJ, Koplin JJ, Roche P, Greaves RF. Advantages 
and challenges of dried blood spot analysis by mass 
spectrometry across the total testing process. EJIFCC 
2016;27:288–317. 
9. Pedersen L, Andersen Ranberg K, Hollergaard M, Nybo M. 
Quantification of multiple elements in dried blood spot 
samples. Clin Biochem 2017;50:703–9.  
10. Food and Drug Administration. Bioanalytical Method 
Validation Guidance for Industry. US; 2018. 
11. European Medicines Agency. Guideline on bioanalytical method 
validation. EMEA/CHMP/EWP/192217/2009 Rev Corr 
2011;44:1–23. 
12. Gonzalez Covarrubias V, Zhang J, Kalabus JL, Relling MV, Blanco 
JG. Pharmacogenetics of human carbonyl reductase 1 (CBR1) in 
livers from black and white donors. Drug Metab Dispos 
 2009;37:400–7.  
13. Brunton L, Chabner BA, Knollman B. Goodman and gilman’s the 
pharmacological basis of therapeuticsmcgraw-hill education; 
2011. Available from: https://books.google.co.id/ 
books?id=e_yAOpyyaowC [Last accessed on 15 Nov 2019]. 
14. Sherwood L. Fundamentals of Human Physiology. Cengage 
Learning; 2011. Available from: https://books.google. 
co.id/books?id=qXwIAAAAQBAJ [Last accessed on 15 Nov 
2019]. 
15. Harmita K, Harahap Y, Supandi. Liquid chromatography-
tandem mass spectrometry (LC-MS/MS). Jakarta: ISFI 
Penerbitan; 2019. 
 
